One major focus is the changing state of T cells exposed to cancer for prolonged periods. Rather than treating exhaustion as a single dysfunctional condition, researchers increasingly view it as a spectrum of differentiation states governed by distinct transcriptional and metabolic programs. Some exhausted T cells retain the capacity to self-renew or respond to checkpoint blockade, while others are more terminally impaired. This distinction could help clinicians choose treatments that restore function without pushing cells beyond recovery. Other work shows that tumor-primed memory T cells can display features of senescence and heightened sensitivity to type I interferons, signaling molecules that are essential for antiviral defense but can worsen immune dysfunction during cancer vaccination if activated at the wrong time. The implication is that vaccine priming, booster schedules and checkpoint inhibition may need to be synchronized with the changing biology of each immune-cell population rather than delivered according to fixed schedules.

The tumor’s immune geography may be just as important as the immune cells themselves. Tissue-resident memory CD4-positive T cells in non-small-cell lung cancer express elevated levels of immune checkpoint molecules and produce XCL1, a chemokine that attracts dendritic cells. Although dendritic cells can help initiate T-cell responses by presenting tumor antigens, the surrounding regulatory environment may blunt the effectiveness of checkpoint blockade. This finding offers a possible explanation for why patients with apparently similar tumors can respond very differently to the same therapy. Beyond the tumor, cancer can remodel the spleen, a major site of immune-cell development and coordination. Changes in splenic architecture and function may alter systemic immunity before treatment even begins, potentially influencing whether circulating T cells, antigen-presenting cells and myeloid populations are prepared to support tumor rejection. The emerging view is that immunotherapy must account for immune organs throughout the body, not only the tumor mass visible on a scan.

Myeloid cells provide another layer of control. Macrophages can engulf malignant cells, present antigens and release inflammatory signals, but tumors frequently reprogram them into tumor-associated macrophages that support growth, blood-vessel formation and immune suppression. Studies in the special issue examine macrophage extracellular traps, web-like structures released by activated macrophages that may promote tumor progression or alter immune-cell behavior. In liver cancer, fibrates—drugs traditionally used to regulate lipid metabolism—enhanced responses to immune checkpoint blockade by inhibiting PLTP-driven infiltration of M2-like macrophages, a population commonly associated with tissue repair and immune suppression. Another study identified LMO7 as a molecular brake on macrophage phagocytosis of cancer cells. Removing or overcoming this brake could strengthen innate immunity, the rapid, antigen-independent arm of defense that operates before highly specific T-cell responses develop. These findings suggest that successful immunotherapy may require simultaneous control of both adaptive lymphocytes and the myeloid cells that determine whether lymphocytes can function inside tumors.

Metabolism and the tumor microenvironment are also being treated as active therapeutic targets rather than passive background conditions. Tumors often accumulate lactate as a consequence of high rates of glycolysis, even when oxygen is available. Lactate can alter immune-cell signaling and drive protein lactylation, a chemical modification that influences gene expression and may stabilize immunosuppressive cell states. By connecting metabolic waste to epigenetic regulation, this research identifies a route through which tumor metabolism can produce lasting changes in immune behavior. The local microbiome adds another variable. A nanozyme designed to target the intratumoral bacterium Peptostreptococcus anaerobius was reported to reverse resistance to ferroptosis, an iron-dependent form of regulated cell death. Reconfiguring microbial niches could therefore make cancer cells more vulnerable to treatment. Meanwhile, blocking secretion of exosomes containing the protein Fgl2, combined with anti-PD-L1 therapy, prevented activation of myeloid-derived suppressor cells. These studies portray tumors as ecosystems in which metabolites, bacteria and extracellular vesicles continuously transmit instructions to immune cells.

Bioengineering is providing tools to rewrite those instructions with greater precision. Manganese–DNA complex extracellular vesicles were designed to reprogram dendritic cells inside pancreatic tumors, potentially improving antigen presentation and the subsequent activation of tumor-specific T cells. Yet another vesicle platform containing ACLY was used to model how engineered particles can induce immunosuppressive macrophage states in liver cancer, illustrating that delivery systems are not biologically neutral: their cargo, surface properties and tissue distribution can determine whether they stimulate or suppress immunity. At the tumor–immune interface, the experimental agent DSP216 simultaneously targets HLA-G and CD47, two signals associated with immune evasion. HLA-G can inhibit lymphocyte activity, while CD47 functions as a “don’t eat me” signal that protects cancer cells from phagocytosis. Blocking both pathways could expose tumors to complementary attacks from adaptive and innate immune cells. Antibody–drug conjugates add another layer of engineering by linking tumor-targeting antibodies to cytotoxic payloads through specialized chemical linkers. Their effectiveness depends on selecting the right antigen, controlling drug release and balancing tumor killing against damage to healthy tissues.

The same design principles are reshaping adoptive cell therapy, in which immune cells are collected, modified or expanded outside the body and then returned to the patient. Chimeric antigen receptor T cells have produced dramatic responses in some blood cancers, but solid tumors present formidable obstacles, including poor cell trafficking, physical barriers, antigen heterogeneity and an immunosuppressive microenvironment. Several studies address these problems by adding new sensing and survival functions to CAR-T cells. An anti-PD-1 nanobody was incorporated into mesothelin-targeting CAR-T cells developed for mesothelioma, allowing the cells to counter checkpoint signaling locally rather than relying entirely on systemic antibody treatment. Humanized, charge-optimized CAR-T cells directed against CSPG4 showed improved activity against head and neck squamous-cell carcinoma, while a CCR4/CD7 bispecific CAR-T design expanded recognition logic by requiring or exploiting two antigenic targets. Researchers are also examining G protein-coupled receptors as a broader control and targeting space for CAR-T engineering. These receptors influence migration, activation and responses to chemokines, making them potential handles for steering therapeutic cells through hostile tumor tissue.

Adoptive therapy is not limited to CAR-T cells. Natural killer cells can recognize stressed or transformed cells without the same antigen-specific receptor requirements as T cells, and their biology offers a complementary route to cancer treatment. In one strategy, NK cells were conjugated to adipose-derived mesenchymal stem cells engineered to express interleukin-15. The stem-cell component was intended to improve tumor localization, while IL-15 supports NK-cell proliferation and cytotoxic activity. Patient-derived tumor-infiltrating lymphocytes are also being advanced as individualized products; work in acral melanoma demonstrates how immune cells extracted from a patient’s own tumor can be expanded and reinfused. Bispecific T-cell engagers, which physically bring T cells into contact with cancer cells, are being humanized for use against tumors in the central nervous system and elsewhere. Nanoparticles may further improve these approaches by controlling the delivery and biodistribution of immunomodulators or chemotherapy, reducing exposure in healthy tissues while concentrating supportive signals near therapeutic cells.

Because tumors deploy several escape mechanisms at once, the collection argues that combinations must be designed mechanistically rather than assembled by trial and error. Reviews of unsuccessful combination trials emphasize the value of biomarker-guided sequencing, dose optimization and adaptive designs that allow researchers to learn during a study and modify treatment arms as evidence accumulates. Artificial intelligence and large language models are being considered for biomarker discovery, patient stratification and treatment optimization, although their usefulness will depend on high-quality clinical and molecular data. Combination studies include antibody–drug conjugates carrying anti-tubulin or topoisomerase I inhibitor payloads alongside radiotherapy, using controlled tumor damage to enhance immune priming. Chemo-immunotherapy is being explored in immune-enriched pancreatic cancer, while an rWTC-MBTA vaccine paired with anti-PD-1 treatment has been evaluated in central nervous system and peripheral B-cell lymphoma. Other approaches combine CDK4/6 inhibitors with checkpoint therapy to regulate tumor-associated macrophages through MIF signaling, or stimulate β2-adrenergic receptors to increase cytotoxic T-cell activity through CXCL10 in p53-deficient head and neck tumors.

Taken together, the studies outline a transition from broad immune stimulation to calibrated immune engineering. Durable responses may require a sequence of interventions: first altering metabolism or suppressive myeloid cells, then improving antigen presentation, guiding immune-cell entry and finally sustaining T-cell or NK-cell activity after tumors begin to shrink. Such strategies could also make treatment more dependent on measurable biological features, including checkpoint expression, macrophage states, chemokine signals, microbial composition, metabolic signatures and the presence of expandable tumor-reactive lymphocytes. The field still faces major challenges, including toxicity, manufacturing complexity, tumor evolution and the difficulty of predicting immune behavior across patients. But the combined research points toward an increasingly programmable form of oncology in which therapies are engineered to disable specific escape mechanisms while preserving the timing and location of immune activation. The goal is not merely to provoke an immune response, but to make that response persistent, adaptable and difficult for cancer to evade.

The McGill research team, operating out of the Rosalind & Morris Goodman Cancer Institute in collaboration with the McGill University Health Centre’s Research Institute, has unveiled a groundbreaking approach that involves the targeted inhibition of two proteins, PTPN1 and PTPN2. By suppressing these proteins, the researchers have unlocked the ability of NK cells to bypass the tumor’s protective barriers, effectively transforming these immune cells into more aggressive and efficient killers of cancer cells.

Preclinical studies demonstrate that this method markedly amplifies NK cell cytotoxicity against a spectrum of challenging tumors including leukemia, glioblastoma, kidney cancer, and the notoriously difficult to treat triple-negative breast cancer. Animal models treated with this novel therapeutic approach exhibited substantial delay in tumor progression, indicating a promising trajectory toward clinical applicability.

Crucially, this technique offers a safer and more controllable alternative to conventional genetic engineering methods often employed in immunotherapy. Genetic modifications to immune cells, while effective, carry long-term risks and irreversible changes that complicate patient safety. Instead, the McGill team’s strategy deploys small-molecule inhibitors that temporarily enhance NK cell activity without altering their genetic code, allowing for reversible modulation of immune responses and improved safety profiles.

The practicality of this approach is amplified by its reliance on allogeneic NK cells sourced from umbilical cord blood donations. These NK cells are extracted, cultured, and banked at the Cellular Therapy Laboratory, facilitated by leaders Pierre Laneuville and Linda Peltier, enabling immediate availability for treating multiple patients. This off-the-shelf method overcomes the logistical issues and time delays characteristic of autologous cell therapies, which necessitate patient-specific cell harvesting and modification.

This scalable, cost-efficient approach could revolutionize the deployment of immunotherapies by simplifying the manufacturing process and expediting treatment delivery. According to Chu-Han Feng, a research scientist on the team, the reversible enhancement of NK cells’ anti-tumor activities via widely available pharmacological agents circumvents the complexities and expenses linked with personalized cellular therapies.

Among the spectrum of malignancies, acute myeloid leukemia (AML), a particularly aggressive hematological cancer characterized by poor prognosis and limited therapeutic options, stands to benefit notably from this intervention. The team is keen on advancing toward clinical trials targeting AML, pending regulatory approvals and additional funding to validate and optimize the treatment’s efficacy in patients.

The underlying mechanisms by which PTPN1 and PTPN2 inhibition boosts NK cell function involve modulation of critical immunological pathways. By enhancing interleukin-2 (IL-2) signaling, a cytokine integral to NK cell proliferation and activation, while simultaneously mitigating the immunosuppressive effects of transforming growth factor beta 1 (TGF-β1), the treatment reprograms NK cells for heightened responsiveness and sustained cytotoxic action within the hostile tumor microenvironment.

This dual mechanism is especially important because tumors frequently exploit TGF-β1 signaling to suppress immune responses and promote tumor immune escape. The capacity to counteract this immunosuppression while promoting activation via IL-2 sets this strategy apart from existing therapies that typically target only one aspect of NK cell regulation.

The detailed findings of this study, titled “PTPN1/PTPN2 inhibition improves NK cancer therapy by enhancing IL-2 and mitigating TGF𝛃1 response,” were published in the April 2026 issue of EMBO Reports. The publication outlines the rigorous experimental framework and provides compelling evidence of the therapeutic promise held by this immunomodulatory approach.

Support for this work was provided by a coalition of funding bodies including the Canadian Institutes of Health Research Foundation, the McGill University Health Centre Foundation, and Genome Canada/Genome Québec, among others. Importantly, the study acknowledges the vital contribution of cord blood donations from volunteer mothers, underscoring the community’s role in advancing cancer immunotherapy research.

The McGill team’s breakthrough represents a major step forward in the quest to harness the immune system’s natural capacities to combat cancer. By offering a safer, faster, and more accessible means to activate NK cells, this approach has the potential to change the landscape of treatment for patients with difficult-to-treat tumors and those who have exhausted conventional options.

With this advancement, the horizon for cancer immunotherapy expands, promising not just incremental improvements but a paradigm shift in how immune-based therapies are developed and deployed. The marriage of biochemical insight and clinical practicality heralds a new chapter in targeted cancer treatments, driven by the power of natural killer cells bolstered through precision pharmacological control.

Subject of Research: Cells
Article Title: PTPN1/PTPN2 inhibition improves NK cancer therapy by enhancing IL-2 and mitigating TGF𝛃1 response
News Publication Date: 15-Apr-2026
Web References: http://dx.doi.org/10.1038/s44319-026-00745-0
References: Feng CH et al., Tremblay ML., EMBO Reports, April 2026
Image Credits: McGill University
Keywords: Cancer, Immunotherapy, Natural Killer Cells, PTPN1, PTPN2, IL-2, TGF-β1, Acute Myeloid Leukemia, Small-molecule drugs, Tumor microenvironment